PET诊断后肿瘤恶性程度增加的风险

IF 0.4 Q3 MEDICINE, GENERAL & INTERNAL
Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk
{"title":"PET诊断后肿瘤恶性程度增加的风险","authors":"Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk","doi":"10.2478/cipms-2022-0007","DOIUrl":null,"url":null,"abstract":"Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.","PeriodicalId":11071,"journal":{"name":"Current Issues in Pharmacy and Medical Sciences","volume":"35 1","pages":"34 - 40"},"PeriodicalIF":0.4000,"publicationDate":"2022-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The risk of increasing tumor malignancy after PET diagnosis\",\"authors\":\"Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk\",\"doi\":\"10.2478/cipms-2022-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.\",\"PeriodicalId\":11071,\"journal\":{\"name\":\"Current Issues in Pharmacy and Medical Sciences\",\"volume\":\"35 1\",\"pages\":\"34 - 40\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Issues in Pharmacy and Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/cipms-2022-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Issues in Pharmacy and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/cipms-2022-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

摘要:本文综述了PET诊断中使用的示踪剂释放的伽马辐射对晚期侵袭性癌症恶性肿瘤增强风险估计的证据。我们的结论是,在许多癌症中,这种现象可能发生,特别是在其发展的晚期具有侵袭性生物学的肿瘤细胞中,例如前列腺癌,黑色素瘤和结直肠癌。此外,我们根据收集到的证据推测,通常用于正电子发射断层扫描(PET)的氟-18 (18F)标记药物(18F-脱氧葡萄糖和18F-胆碱)可导致诊断癌症的恶性增强,表现为加速邻近组织的浸润,加速转移和/或放射和化疗耐药性。在这篇综述中,对未来验证这一概念的研究提出了一些建议。如果我们的担忧是合理的,那么将来在决定是否对一些晚期侵袭性癌症患者进行PET监测时考虑这一假设可能是合适的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The risk of increasing tumor malignancy after PET diagnosis
Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Issues in Pharmacy and Medical Sciences
Current Issues in Pharmacy and Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
0.80
自引率
0.00%
发文量
28
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信